BRAF and Miyoshi myopathy: The reduced CMV seroprevalence in the MM group was observed across patients with both BRAF mutant and wild-type (WT) disease, although the effect was accentuated in BRAF mutants (BRAF-mutated: OR = 0.44, P = 0.0018; BRAF-WT: OR = 0.58, P = 0.026; Fig. 6a).